Skip to main
CORT
CORT logo

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics Inc. is poised for significant growth, with annual sales of Korlym projected to increase by 19% to 26% year-over-year for FY2025, reflecting strong underlying demand and the company's ability to overcome recent supply chain challenges. The encouraging clinical trial results for relacorilant, particularly in combination with nab-paclitaxel for advanced ovarian cancer, highlight the compound's potential to significantly improve patient outcomes, further enhancing the company's prospects. Additionally, the ongoing expansion of the Cushing’s syndrome market and anticipated improvements in production capacity indicate that Corcept could tap into a multi-billion-dollar market in the coming years.

Bears say

Corcept Therapeutics faces potential near-term earnings challenges, as the departure of Optime and anticipated downward revisions to 2025 revenue guidance may negatively impact investor sentiment. The company has lowered its Korlym sales forecast by approximately 10% for the latter half of 2025, which has resulted in a projected 2025 sales estimate of $824 million, falling below the previously expected range of $850 million to $900 million. Additionally, delays in management's strategy to establish operational pharmacies are exacerbating supply chain issues, contributing to increased uncertainty regarding future revenue growth.

Corcept Therapeutics (CORT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Corcept Therapeutics (CORT) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $139, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $139, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.